Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...196197198199200201202203204205206...208209»
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment change:  A Study to Evaluate SHR-1210 in Subjects With Advanced HCC (clinicaltrials.gov) -  Sep 26, 2017   
    P2/3,  N=220, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2017 N=60 --> 220
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Monotherapy, Metastases:  Apatinib for the Elderly Advanced Gastric Cancer (clinicaltrials.gov) -  Aug 23, 2017   
    P2,  N=60, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Enrollment change:  Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors (clinicaltrials.gov) -  Aug 9, 2017   
    P1,  N=50, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016 N=70 --> 50
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    New trial:  Apatinib for Resectable Colorectal Cancer (clinicaltrials.gov) -  Jul 27, 2017   
    P=N/A,  N=80, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open:  Apatinib for Resectable Colorectal Cancer (clinicaltrials.gov) -  Jul 27, 2017   
    P=N/A,  N=80, Recruiting, 
    N=70 --> 50 Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. (Pubmed Central) -  Jul 26, 2017   
    At this time, only two biologic therapies are recommended by the National Comprehensive Cancer Network (NCCN): trastuzumab for patients with esophageal/esophagogastric or gastric adenocarcinomas with HER2 overexpression and ramucirumab, a VEGFR-2 inhibitor, as a second-line therapy for metastatic disease. However, recent reports of increases in overall and progression-free survival for agents including pertuzumab, apatinib, and pembrolizumab will likely increase the use of targeted biologic therapy in clinical practice for esophageal and gastric malignancies.
  • ||||||||||  Biomarker, Journal:  Emerging Treatment using Tubulin Inhibitors in Advanced Non-Small Cell Lung Cancer. (Pubmed Central) -  Jul 26, 2017   
    The article then provides a summary of novel tubulin inhibitors, including cabazitaxel, eribulin, ixabepilone, patupilone, plinabulin, new colchicine analogues and others...Expert Opinion: Tubulin inhibitors will likely continue to play important roles in NSCLC management due to the advent of novel agents and combinations. Through further understanding of tumor biology, investigation of drug resistance, and development of predictive biomarkers, we will be better positioned to incorporate microtubule inhibition into patient specific treatment strategies.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Trial primary completion date:  Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) (clinicaltrials.gov) -  Jul 6, 2017   
    P3,  N=400, Active, not recruiting, 
    Through further understanding of tumor biology, investigation of drug resistance, and development of predictive biomarkers, we will be better positioned to incorporate microtubule inhibition into patient specific treatment strategies. Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Dec 2017